Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618821 | 0.99 | MAPT (0.36) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| Bromide SCHEMBL6597813 | 0.90 | MAPT (0.34) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL6611866 | 0.82 | POLB (0.38) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL6598021 | 0.81 | KMT2A (0.45) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL1193657 | 0.80 | KMT2A (0.44) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| Bromide SCHEMBL6598138 | 0.78 | MAPT (0.32) | ALDH1A1MAPTKMT2AMEN1POLB | |
| Bromide SCHEMBL1194391 | 0.78 | SMN1; SMN2 (0.38) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL6597394 | 0.77 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL3689760 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1MAPTKMT2AMEN1LMNA | |
| SCHEMBL6598296 | 0.75 | SMN1; SMN2 (0.38) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | claimed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | claimed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | claimed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | claimed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | claimed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | claimed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ALDH1A1 132/4885MAPT 4105/4885KMT2A 3588/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | ALDH1A1 528/4885MAPT 4535/4885KMT2A 3384/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | ALDH1A1 226/4885MAPT 4043/4885KMT2A 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.